http://www.sabpa.org/web/news_details.php?ID=449

Date：March 23, 2013, Saturday, 8:30am To 3:00pm（Lunch will be provided）
Location：Institute of Americas, UCSD
                Direction available at http://sabpa.org/web/IOA_UCSD-directions-map.pdf

Registration：https://www.123signup.com/register?id=bmgsg
                $20 for online registration, $10 for students and post-docs.  $40 for on-site registration,
                Online registration ends March 20, 2012

For the past two decades, biologics have revolutionized the treatment of diseases such as rheumatoid arthritis, psoriasis, Crohn’s disease, and multiple sclerosis, and are widely used in treating a variety of cancers.  Biologics is a rapidly developing field of therapeutics and there is a trend for pharmaceutical and biotech industries to drift toward biologics development due to the promise of biologic drugs.

At the SABPA Science & Technology Forum XI, we bring together leaders in academic and pharma/biotech industry to discuss current trend in biologics discovery and development, as well as challenges facing the field. The presentations will address new technologies in discovering novel biologic therapeutics including the use of unnatural amino acids, somatic hypermutation and directed molecular evolution as well as developing biologics delivery platform.  The meeting will cover therapeutic antibodies, proteins, peptides, vaccines and therapeutic areas from cancers, autoimmune to cardiovascular diseases.

Event Program

• 8:00-8:30 Registration & Breakfast
• 8:30-8:35 Opening Remarks
• 8:35-8:40 Chairperson of session 1
• 8:40-9:15 Peter Schultz, Ph.D.
  Professor of Chemistry, Scripps Research Institute; and Director of California Institute for Biomedical Research
  Title:  A Chemist's Foray into Translational Medicine.
• 9:15-9:45 Thomas F Bumol, Ph.D.
  Vice President of Biotechnology and Autoimmunity, Lilly Research Laboratories, Lilly Biotechnology Center-San Diego
  Title：Biotechnology as a Sustainable Source of Pharmaceutical Innovation：the Lilly Biotechnology Strategy.
• 9:45-10:15 David King, Ph.D.
  Chief Scientific Officer, AnaptysBio Inc
  Title：Generating Improved Antibody Therapeutics through Somatic Hypermutation in vitro
• 10:15-10:40 Refreshment Break, Exhibit & Networking
• 10:40-10:45 Chairperson of session 2
• 10:45-11:15 Jeremy Barton, MD.
  Vice President, Biotherapeutics Development, Pfizer
  Title：Antibody Drug Conjugates：Blockbusters of the Next Decade?
• 11:15-11:45 Henry Ji, Ph.D.
  Chief Executive Officer and President, Sorrento Therapeutics
  Title：The G-MAB®Library Technology – Discovery and Development of New Human Therapeutic Antibodies
• 11:45-12:45 Panel Discussion：Biologics Development
  Moderator                                      
  Steve Prestrelski, Ph.D., M.B.A.
  Chief Scientific Officer, Xeris Pharmaceuticals, Inc.
  Panelist
  1. Bhawanjit Brar, Ph.D., Senior Director, Zensun USA
  2. Jean I Liu, M.S., J.D., Vice President, General Counsel and Secretary, Halozyme Therapeutics, Inc.
  3. Brenden S. Gingrich, Ph.D., J.D., Partner, Knobbe Martens
  4. Tim Tian, Ph.D., Senior Scientist, Laureate BioPharma
  5. Olivier Laurent, Ph.D., Director, Protein Science, CovX
• 12:45-12:50 Closing Remarks:
• 12:50-2:30 Lunch

SABPA www.sabpa.org
Contact：jianfengpan@hotmail.com 314-703-7327（cell）